Fig. 4: Mean VA at the start and end of year 2 by injection frequency in years 1 and 2 in eyes with MO secondary to BRVO.

*P < 0.001 compared with the change in the ≥7/≥7-injections subcohort. BRVO branch retinal vein occlusion, ETDRS Early Treatment Diabetic Retinopathy Study, MO macular oedema, VA visual acuity.